The NCCN in 2019 updated its prostate cancer guideline to focus on the roles of germline and somatic genetic testing and risk stratification with nomograms and tumor multigene molecular testing, among other topics. These five questions will test your knowledge of the update.
Question 1
The expanded National Comprehensive Cancer Network (NCCN) criteria for a positive family history of prostate cancer includes which of the following?
A. Ashkenazi Jewish ancestry
B. First-order male relatives with prostate cancer history before age 60
C. Multiple cancers diagnosed on the same side of one’s family
D. All of the above
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.